MDS

This study looks at whether using stem cells from a younger, more distant relative leads to better survival than using cells from an older immediate family member for people with leukemia or myelodysplastic syndrome (MDS). About 232 patients aged 13-78 who need a transplant but l…

This study tests an experimental drug called vibecotamab in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer did not fully respond to standard treatments. The drug works by helping the immune system find and destroy cancer cells that carry a…

This study looks at whether adding venetoclax to standard chemotherapy (HMAs) works better than chemotherapy alone for people newly diagnosed with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 224 adults will be observed to see how m…

This study tests a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and CNL). The goal is to see if it can shrink enlarged spleens and improve blood counts. Participants take the drug by mouth and are monitored for response and side effects.

This study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in people whose MDS or AML came back after a stem cell transplant. The goal is to find the best dose and see if the treatment can control the cancer. About 55 adults with relapsed dis…

This study follows 60 people with lower-risk myelodysplastic neoplasms (MDS) for 6 months to see how different blood transfusion strategies affect their quality of life and health costs. Participants use a smartphone app (or paper forms) to answer weekly questions about how they …